BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
1401 results:

  • 1. Inhibition of prostate cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of akt and Activation of AMPK Signaling.
    Nadile M; Sze NSK; Fajardo VA; Tsiani E
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732504
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
    Kadry MO; Abdel-Megeed RM
    PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Revealing the mechanism of ethyl acetate extracts of Semen Impatientis against prostate cancer based on network pharmacology and transcriptomics.
    Hu B; Wang C; Wu Y; Han C; Liu J; Chen R; Wang T
    J Ethnopharmacol; 2024 Aug; 330():118228. PubMed ID: 38643863
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the treatment of prostate cancer.
    Zheng L; Zhang Y; Mei S; Xie T; Zou Y; Wang Y; Jing H; Xu S; Dramou P; Xu Z; Li J; Zhou Y; Niu MM
    J Med Chem; 2024 May; 67(9):7130-7145. PubMed ID: 38630077
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating akt signaling with induction of senescence and apoptosis.
    Brown LK; Kanagasabai T; Li G; Celada SI; Rumph JT; Adunyah SE; Stewart LV; Chen Z
    Prostate; 2024 Jun; 84(9):877-887. PubMed ID: 38605532
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Mechanism study on the effect of androgen antagonism in prostate cancer].
    Song X; Song Q; Wang R; Zuo QJ; Zhang ZY
    Zhonghua Nan Ke Xue; 2023 May; 29(5):402-408. PubMed ID: 38602755
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells.
    Atri Roozbahani G; Kokal-Ribaudo M; Heidari Horestani M; Pungsrinont T; Baniahmad A
    Cell Commun Signal; 2024 Apr; 22(1):219. PubMed ID: 38589887
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Unveiling the Anticancer Potential of Pasak Bumi (Eurycoma Longifolia Jack) Root Extract in prostate cancer treatment.
    Rahman EY; Kania N; Sutapa H; Purnomo AF; Panghiyangani R; Skripsiana NS
    Med Arch; 2024; 78(2):117-121. PubMed ID: 38566865
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
    Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
    PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
    Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
    Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Decision regret of cancer patients after radiotherapy: results from a cross-sectional observational study at a large tertiary cancer center in Germany.
    Rühle A; Wieland L; Hinz A; Mehnert-Theuerkauf A; Nicolay NH; Seidel C
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):167. PubMed ID: 38546873
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic prostate cancer.
    Uzelac M; Xin R; Ongkeko WM
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Scutellarin, a flavonoid compound from Scutellaria barbata, suppresses growth of breast cancer stem cells in vitro and in tumor-bearing mice.
    Ma H; Yue GG; Lee JK; Gao S; Yuen KK; Cheng W; Li X; Lau CB
    Phytomedicine; 2024 Jun; 128():155418. PubMed ID: 38518647
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Hydroxychloroquine interaction with phosphoinositide 3-kinase modulates prostate cancer growth in bone microenvironment: In vitro and molecular dynamics based approach.
    Abdullah KM; Sharma G; Qais FA; Khan I; Takkar S; Kaushal JB; Kanchan RK; Sarwar T; Chakravarti B; Siddiqui JA
    Int J Biol Macromol; 2024 May; 266(Pt 1):130912. PubMed ID: 38513896
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tyrosine phosphatase
    Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
    Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
    Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
    Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Flubendazole suppresses VEGF-induced angiogenesis in HUVECs and exerts antitumor effects in PC-3 cells.
    Zhang B; Zhao J; Kang D; Wang Z; Xu L; Zheng R; Liu A
    Chem Biol Drug Des; 2024 Mar; 103(3):e14503. PubMed ID: 38480495
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of akt-mediated survival mechanisms in prostate cancer.
    Eberlein C; Williamson SC; Hopcroft L; Ros S; Moss JI; Kerr J; van Weerden WM; de Bruin EC; Dunn S; Willis B; Ross SJ; Rooney C; Barry ST
    Br J Cancer; 2024 May; 130(8):1377-1387. PubMed ID: 38396173
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Capivasertib: First Approval.
    Shirley M
    Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
    Smith TAD; West CML; Joseph N; Lane B; Irlam-Jones J; More E; Mistry H; Reeves KJ; Song YP; Reardon M; Hoskin PJ; Hussain SA; Denley H; Hall E; Porta N; Huddart RA; James ND; Choudhury A
    EBioMedicine; 2024 Mar; 101():105032. PubMed ID: 38387404
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 71.